Ascendis Pharma (spons. ADRs) Aktie
Mit dem Broker, der Top-Insights, geprüfte Analysen
und Trading ab 0 € vereint (zzgl. Spreads).
Ascendis Pharma (spons. ADRs) Aktie Analyse
| 24.01.19 | Ascendis Pharma (spons. ADRs) Overweight | Cantor Fitzgerald | |
| 26.06.18 | Ascendis Pharma (spons. ADRs) Buy | Stifel, Nicolaus & Co., Inc. | |
| 26.09.16 | Ascendis Pharma (spons. ADRs) Outperform | Wedbush Morgan Securities Inc. |